Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHB-171 in Healthy Participants and Chronic Hepatitis B Participants
NCT07511218Phase 1Recruiting
- Sponsor
- AusperBio
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised trial of AHB-171 in Chronic Hepatitis B (CHB) (2 arms), sponsored by AusperBio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 48 weeks, Severity of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 48 weeks and 4 more. Started Apr 2026; status: recruiting.
02
Drugs
AHB-171
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07511218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07511218.